Search results
Showing 3801 to 3850 of 4138 results for patient
advice from NICE, clinical, economic, health technology assessment and patient experts. We also offer this service in partnership with...
Supporting the health and care system to implement virtual wards
Virtual wards (also known as hospital at home) provide hospital level care at home.
The wider determinants of health are a broad range of social, economic and environmental factors that influence people’s health and well-being.
The Marmot Review concluded that being in good employment is usually protective of health while unemployment, particularly long term unemployment, contributes significantly to poor health.
The Marmot Review summarised the importance the impact of addressing inequalities in health in later life and investing in the early years to preventing ill health later in life.
Find individual child abuse and neglect recommendations quickly and links to full guideline.
Support for delivering quality, safety and efficiency in the optimisation of medicines.
We work with the clinical classifications service of NHS Digital to provide relevant clinical coding information for interventional procedure and medical technologies guidance.
This resource is intended to demonstrate how our guidance can be used in the Care Quality Commission (CQC) assessment process.
This resource is intended to demonstrate how our guidance can be used in the Care Quality Commission (CQC) assessment process.
This resource is intended to demonstrate how our guidance can be used in the Care Quality Commission (CQC) assessment process.
This resource is intended to demonstrate how our guidance can be used in the Care Quality Commission (CQC) assessment process.
Tell us about an interventional procedure you think should be assessed by NICE.
Information and links to key resources that will help you keep your practice up-to-date.
treating cystic fibrosis patients with: Ivacaftor, tezacaftor and elexacaftor (Kaftrio®) in combination with ivacaftor for...
The innovative hybrid closed loop (HCL) systems offer improved blood sugar control and can transform daily life for families managing this complex condition.
Check to see if you're entitled to access a range of content purchased by the NHS. If you are eligible, you can register for an OpenAthens account using our online form.
Summaries of the best available evidence for selected medicines that are considered to be of significance to the NHS.
NICE leads the way in approving breakthrough treatment for multiple myeloma
People in England will become the first in the world to receive belantamab mafodotin for this indication following our recommendation and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) approval earlier this year.
We’re bringing our guidance together by topic, so that it’s all in one place, clearer to understand and easier to use.
In virtual wards, people can receive virtual and technology-assisted treatment, assessment, and monitoring.
In virtual wards, patients remain at home to receive hospital-level care. Our guidance can help you determine if patients are suitable for admission to the virtual wards system.
In a virtual ward setting, you make assessments at home to support clinical decision-making. Our guidance can help you give advice by highlighting areas to consider and standards of care.
prescribing Measuring the use of NICE guidance Into practice resources Patient decision aids Implementation help and advice Cost saving,...
Our guidance helps you hand over care and ensure people are safely transitioned out of the virtual ward environment.
Dr Sarah Byron discusses how NICE is transforming to ensure more digital health technologies are adopted by the NHS.
These are the main stages in the multiple technology appraisal process used before April 2018.
Over 4,200 people set to benefit after we recommend daily pill to treat rare chronic kidney disease
New treatment sparsentan has been found to slow down the progression of kidney damage, which will change people’s lives for the better.
New weekly treatment option approved for people with haemophilia B
Our final draft guidance published today recommends marstacimab (also called Hympavzi and made by Pfizer) for treating the severe form of blood disorder haemophilia B in people 12 years and over.
Up to 1,000 women a year could benefit from new at-home treatment for endometriosis
Today we've recommended a new treatment option for symptoms of endometriosis that can be taken at home.
AI skin cancer detection system gets green light for conditional NHS use
An artificial intelligence system for potential skin cancer has been conditionally recommended for use in the NHS for the next three years while further evidence is collected.
Technology recommended for people with chronic tic disorders and Tourette syndrome
Final guidance recommends one digital therapy to help children and young people manage their condition.
Cutting-edge robotic surgery gets green light as 11 systems are recommended
Eleven cutting-edge robotic surgery systems have been approved for use, potentially transforming care for thousands of NHS patients undergoing soft tissue and orthopaedic procedures.
Thousands of people a year could benefit from new twice-a-day tablet for advanced breast cancer
We've published final draft guidance recommending capivasertib with fulvestrant, which means the treatment will be funded immediately through the Cancer Drugs Fund.
Hundreds of people in England to benefit from take-at-home tablet bladder cancer treatment
Today, for the first time, we have given the green light to a targeted treatment for the most common form of bladder cancer.
Millions of people living with long-term neurological conditions across England face inconsistent access to vital rehabilitation services, according to NICE.
Record number of positive recommendations for blood cancer treatments
Around 5,000 blood cancer patients could benefit from 13 treatments recommended by NICE in 2024.
Podcasts 20 January 2025 Listen About this episode We're joined by patient advocate Jules Fielder and leading oncologists from Roy...
HST routing criteria: encouraging innovation in the treatment of ultra-rare diseases
Our chief medical officer, Professor Jonathan Benger, explains the crucial role the HST programme plays in encouraging innovation in the treatment of ultra-rare diseases. He also highlights why effective routing is essential to getting the best care to patients across the NHS.
First-ever NHS treatment approved for advanced Hodgkin lymphoma
New combination therapy offers hope to 800 people annually with late-stage blood cancer.
Changes approved to the routing criteria for highly specialised technologies
At its meeting on 19 March our Board approved changes to the criteria we use to decide which treatments should be evaluated, to ensure more consistent, predictable and transparent decisions.
Annual BMI checks recommended for adults with long-term conditions
We've published a draft quality standard calling for yearly BMI and waist-to-height measurements to help prevent weight-related complications.
Today we've recommended the first long-term daily pill to treat endometriosis that could transform how this painful condition is managed.
First licensed treatment for ultra-rare immune disorder recommended
Leniolisib is the first ever treatment for activated phosphoinositide 3-kinase delta syndrome (APDS) licensed for use in the NHS in England.
Second consultation launched on NHS funding for Alzheimer's treatments
Cost and evidence gaps remain barriers to approving funding in the NHS for donanemab and lecanemab.
Harnessing expertise to improve patient access to innovative health technologies
Introducing the Medicines and Medical Devices Access Initiative (MMD): a new collaboration that aims to improve patient access to safe, clinically and cost-effective healthcare products.
NICE publishes final draft guidance recommending efanesoctocog alfa as an option for treating and preventing bleeding in people aged 2 and over with severe haemophilia A.
NICE approves groundbreaking one-off gene therapy for severe sickle cell disease
People in England with severe sickle cell disease will be among the first to receive treatment using revolutionary CRISPR gene editing technology, following publication of our final draft guidance today.
New option for adult leukaemia patients as we recommend treatment
Today we've recommended an immunotherapy treatment that could prevent blood cancer from returning in adults who've responded well to initial therapy.
Green light for groundbreaking personalised cancer therapy that reprogrammes immune system
We've recommended an innovative one-off cell therapy that could give hundreds of lymphoma patients precious extra time with loved ones.